Assembly Biosciences, Inc. (ASMB)

NASDAQ: ASMB · IEX Real-Time Price · USD
1.95 0.06 (3.17%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap93.33M
Revenue (ttm)7.29M
Net Income (ttm)-109.02M
Shares Out47.86M
EPS (ttm)-2.66
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume855,850
Open1.85
Previous Close1.89
Day's Range1.84 - 1.95
52-Week Range1.84 - 7.02
Beta0.66
AnalystsBuy
Price Target10.00 (+412.8%)
Earnings DateNov 4, 2021

About ASMB

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, L...

IndustryBiotechnology
IPO DateDec 17, 2010
Employees139
Stock ExchangeNASDAQ
Ticker SymbolASMB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ASMB stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 412.82% from the latest price.

Price Target
$10.00
(412.82% upside)
Analyst Consensus: Buy

News

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

1 week ago - GlobeNewsWire

Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

1 week ago - GlobeNewsWire

Down 30.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Assembly Biosciences (ASMB)

Assembly Biosciences (ASMB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in...

1 month ago - Zacks Investment Research

Assembly Biosciences Presents New Data at AASLD The Liver Meeting™ Highlighting the Progress of its HBV Core Inhibito...

Newly selected preclinical core inhibitor candidate, ABI-4334, demonstrates single-digit nanomolar potency against both pgRNA encapsidation and cccDNA formation

2 months ago - GlobeNewsWire

Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®

HBV core inhibitor data will be highlighted in one oral and two poster presentations, including one late breaking HBV core inhibitor data will be highlighted in one oral and two poster presentations, in...

2 months ago - GlobeNewsWire

Assembly Bio Announces October Conference Participation

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

3 months ago - GlobeNewsWire

Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158

--Decision follows observation of elevated alanine transaminase (ALT) levels in Phase 2 study --Company will focus on advancing ongoing triple combination studies and earlier pipeline candidates

4 months ago - GlobeNewsWire

Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

4 months ago - GlobeNewsWire

Assembly Biosciences (ASMB) Reports Q2 Loss, Lags Revenue Estimates

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 14.06% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) --  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B...

5 months ago - GlobeNewsWire

Assembly Bio Announces Key Promotions to Leadership Team

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) --  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B...

5 months ago - GlobeNewsWire

Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Nobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences Board of Directors

Esteemed academic and industry virologist discovered hepatitis C virus (HCV); brings 40+ years of scientific and drug development experience Esteemed academic and industry virologist discovered hepatiti...

5 months ago - GlobeNewsWire

Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021

SOUTH SAN FRANCISCO, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

7 months ago - GlobeNewsWire

Assembly Biosciences (ASMB) Reports Q1 Loss, Lags Revenue Estimates

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 12.66% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Earnings Preview: Assembly Biosciences (ASMB) Q1 Earnings Expected to Decline

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

3 Net Current Asset Value Stocks

There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they are convinced they can gain from these kinds of investments after the market has reasses...

Other symbols:LUMOUTSI
9 months ago - GuruFocus

Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection

Assembly Biosciences Inc (NASDAQ: ASMB) and Arbutus Biopharma Corp (NASDAQ: ABUS) initiated a Phase 2 trial evaluating the former's vebicorvir (VBR), combined with the latter's AB-729 and standard-of-ca...

Other symbols:ABUS
10 months ago - Benzinga

Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy

Assembly Biosciences Inc (NASDAQ: ASMB) will not initiate Phase 3 studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive therapy (CST), as the company wants to focus on hepatitis B therapies...

10 months ago - Benzinga

Assembly Biosciences (ASMB) Reports Q4 Loss, Lags Revenue Estimates

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of -23.33% and -72.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Vir...

- Prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel tar...

10 months ago - GlobeNewsWire

Will Assembly Biosciences (ASMB) Report Negative Q4 Earnings? What You Should Know

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

Assembly Bio Announces Upcoming Investor Events

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

10 months ago - GlobeNewsWire

Assembly Biosciences to Wind-Down Microbiome Program

Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio

1 year ago - GlobeNewsWire